Retatrutide
Triple-agonist (GLP-1 / GIP / glucagon) research peptide studied for metabolic pathways, appetite regulation, and body composition research.
Mechanism of action
Retatrutide is a synthetic triple-agonist peptide that binds the GLP-1, GIP, and glucagon receptors. In published preclinical and clinical literature, simultaneous activation of these three incretin and metabolic pathways has been associated with effects on energy expenditure, insulin secretion, and adiposity in research models.
Retatrutide is a single molecule designed to flip three metabolic switches at once — the same switches that tell your body to release insulin, feel full after a meal, and burn stored energy. Hitting all three at the same time is what makes it stand out from earlier peptides in the research literature.
Research areas
- · How the brain decides you're full
- · How fast the body burns energy at rest
- · How fat and lean mass change over time
History & discovery
Developed by Eli Lilly and first disclosed in the medical literature around 2022, retatrutide entered Phase 2 trials in 2023 (Jastreboff et al., NEJM). It builds on the dual-agonist concept pioneered by tirzepatide by adding glucagon-receptor activity to the mix.
Reconstitution & handling
Lyophilized peptides are typically reconstituted with bacteriostatic water and stored refrigerated after reconstitution. Use the dosing calculator to work out concentrations for your research preparation.
Open reconstitution calculatorAssay & QC notes
Each lot is tested by reversed-phase HPLC for purity, confirmed by mass spectrometry for identity, and screened for endotoxin contamination.